Several kidney and cardiovascular outcome studies in type 2 diabetes have indeed demonstrated that there are important advantages to using SGLT2 inhibitor therapy, including mortality benefits (for review see (Alicic et al., 2019) (Kanduri et al., 2020). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.